Molecular Mechanisms and Therapeutics for SCA17

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Spinocerebellar ataxia type 17 (SCA17) is a neurodegenerative disorder resulting from polyglutamine (polyQ) expansion in the TATA box-binding protein (TBP).
• Despite ubiquitous TBP expression, SCA17 exhibits selective, late-onset neurodegeneration, a hallmark of polyQ diseases.
• The precise pathogenesis of polyQ diseases remains incompletely understood, with no current effective treatments.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying SCA17 pathogenesis.
• To focus on transcriptional dysregulation as the primary cause of neurodegeneration in SCA17.
• To identify potential therapeutic strategies for SCA17.

Main Methods:

• This review synthesizes existing research on SCA17 molecular mechanisms.
• Focuses on the role of TBP polyQ expansion in transcriptional alterations.
• Examines evidence linking transcriptional dysregulation to neurodegeneration.

Main Results:

• Polyglutamine expansion in TBP leads to significant transcriptional dysregulation.
• Altered gene expression patterns are strongly implicated in the selective neurodegeneration observed in SCA17.
• Mutant TBP's impact on the transcription process is a key pathogenic event.

Conclusions:

• Transcriptional dysregulation is identified as the major cause of SCA17.
• Reversing TBP-induced transcriptional alterations presents a promising therapeutic avenue.
• Reducing the expression of mutant TBP offers another potential strategy for treating SCA17.